NewAmsterdam Pharma Co N.V.
NAMSW- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001936258
In the last 90 days, NewAmsterdam Pharma Co N.V. insiders filed 1 open-market purchase and 3 sales; 9 institutions reported holding it in 13F filings for Q2 2026, worth $28.1M in total; no superinvestor holds it.
Other share classesNAMS
Open-market trades, last 90 days
Open-market purchases (P) and sales (S) by NewAmsterdam Pharma Co N.V. insiders, counted by Form 4 filing. Trades with a flagged price and duplicate filings are left out.
- Open-market buys
- 1 filing
- 1 insider, $226.5K in total
- Open-market sells
- 3 filings
- 3 insiders, $6.59M in total
- Insiders trading
- 4
- Net value
- −$6.36M
- Purchases minus sales
Insider roster
Directors, officers and 10% owners who have filed a Form 4 for NewAmsterdam Pharma Co N.V., current and former, most recent filer first. Last reported holding is the position after the last non-derivative trade in their latest filing.
| Name | Title | Last reported holding | Last filing | Filings, past year |
|---|---|---|---|---|
| Davidson Michael H. | Chief Executive Officer | 792,923 | Sep 15, 2026 | 4 |
| Smither John W | Director | 8,760 | Sep 9, 2026 | 2 |
| Gunning Robert William | Vice President, Controller | 3,200 | Sep 3, 2026 | 1 |
| Kastelein Johannes Jacob Pieter | Chief Scientific Officer | 69,302Indirect | Aug 25, 2026 | 4 |
| Kooij Louise Frederika | Chief Accounting Officer | 24,353 | Jul 22, 2026 | 7 |
| Lange Louis G | Director | 10,360 | Mar 12, 2026 | 3 |
| Somaiya Mayur Ian | Chief Financial Officer | 58,382 | Jan 22, 2026 | 2 |
| Lewis William | Director | 10,360 | Jan 9, 2026 | 1 |
| Gulfo Adele M. | Director | 14,260 | Jan 9, 2026 | 1 |
| McKenna Mark C. | Director | 10,360 | Jan 9, 2026 | 1 |
| van der Kamp Hilde Johanna | Director | 10,360 | Jan 9, 2026 | 1 |
| Topper James N | Director | 3,028,524Indirect | Sep 17, 2025 | 0 |
| Kling Douglas F | Chief Operating Officer | 44,000 | Jul 17, 2025 | 0 |
| Marino Michael F III | See Remarks | 55,000 | Jun 3, 2025 | 0 |
| Audet Juliette Berangere | See Remarks | 15,104 | May 2, 2025 | 0 |
| Jones William A Jr | Chief Commercial Officer | 43,000 | Jan 7, 2025 | 0 |
| Forbion Capital Fund IV Cooperatief U.A. | 10% Owner | 10,656,172Indirect | Jan 2, 2025 | 0 |
| Forbion Growth Opportunities Fund I Cooperatief U.A. | 10% Owner | 10,656,172Indirect | Jan 2, 2025 | 0 |
| Forbion Growth Management B.V. | 10% Owner | 10,656,172Indirect | Jan 2, 2025 | 0 |
| Forbion IV Management B.V. | 10% Owner | 10,656,172Indirect | Jan 2, 2025 | 0 |
| ForGrowth NAP B.V. | 10% Owner | 10,656,172Indirect | Jan 2, 2025 | 0 |
| BCIP Life Sciences Associates, LP | 10% Owner | – | Dec 17, 2024 | 0 |
| Bain Capital Life Sciences Investors, LLC | 10% Owner | – | Dec 17, 2024 | 0 |
| Bain Capital Life Sciences Fund II, L.P. | 10% Owner | – | Dec 17, 2024 | 0 |
| Bain Capital Life Sciences Investors II, LLC | 10% Owner | – | Dec 17, 2024 | 0 |
| BCLS II Investco, LP | 10% Owner | – | Dec 17, 2024 | 0 |
| BCLS II Investco (GP), LLC | 10% Owner | – | Dec 17, 2024 | 0 |
| Bain Capital Life Sciences Fund III, L.P. | 10% Owner | – | Dec 17, 2024 | 0 |
| BCLS Fund III Investments GP, LLC | 10% Owner | – | Dec 17, 2024 | 0 |
| Bain Capital Life Sciences III General Partner, LLC | 10% Owner | – | Dec 17, 2024 | 0 |
| BCLS Fund III Investments, LP | 10% Owner | – | Dec 17, 2024 | 0 |
Insider trades
Each row adds up one type of transaction in one Form 4 filing. Only open-market purchases (P) and sales (S) are shown by default; use the filters to see grants, option exercises and other codes.
| Filed (ET) | Trade date | Filing delay | Insider | Transaction | Shares | Avg price | Value | Holding change | Flags |
|---|---|---|---|---|---|---|---|---|---|
| Mar 2, 2026 (view filing) | Mar 2 | Same day | Davidson Michael H.Chief Executive Officer | SSale | −443.7K | $33.25 | −$14.8M | −71.8%174.1K after | |
| Mar 9, 2026 (view filing) | Mar 5-9 | 4 days | Kastelein Johannes Jacob PieterChief Scientific Officer | SSale | −300.0K | $30.30 | −$9.09M | −81.2%69.3K after | 3 lots10b5-1 |
| Mar 10, 2026 (view filing) | Mar 6 | 4 days | Lange Louis GDirector | SSale | −28.2K | $29.41 | −$829.0K | −100.0%0 after | |
| Mar 12, 2026 (view filing) | Mar 11 | 1 day | Lange Louis GDirector | SSale | −44.6K | $30.42 | −$1.36M | −81.2%10.4K after | 2 lots |
| May 27, 2026 (view filing) | May 26 | 1 day | Kooij Louise FrederikaChief Accounting Officer | SSale | −65.0K | $35.69 | −$2.32M | −72.7%24.4K after | 10b5-1 |
| Jun 24, 2026 (view filing) | Jun 22 | 2 days | Kooij Louise FrederikaChief Accounting Officer | SSale | −40.0K | $30.20 | −$1.21M | −62.2%24.4K after | 2 lots10b5-1 |
| Jul 22, 2026 (view filing)4:05 PM ET | Jul 20 | 2 days | Kooij Louise FrederikaChief Accounting Officer | SSale | −105.0K | $30.34 | −$3.19M | −81.2%24.4K after | 3 lots10b5-1 |
| Aug 25, 2026 (view filing)4:30 PM ET | Aug 24 | 1 day | Kastelein Johannes Jacob PieterChief Scientific Officer | SSale | −125.0K | $26.91 | −$3.36M | −64.3%69.3K after | 10b5-1 |
| Sep 9, 2026 (view filing)4:30 PM ET | Sep 4 | 5 days | Smither John WDirector | SSale | −1.60K | $25.32 | −$40.5K | −15.4%8.76K after | |
| Sep 15, 2026 (view filing)4:30 PM ET | Sep 14 | 1 day | Davidson Michael H.Chief Executive Officer | PPurchase | +10.0K | $22.65 | +$226.5K | +1.3%792.9K after |